2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
9
Myelodysplastic Syndromes
3
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Unresectable Colorectal Cancer
1
Triple Negative Breast Neoplasms
1
Sezary Syndrome
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Myeloid Malignancies
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Carcinoma, Transitional Cell
1
Brain Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
pembrolizumab
161
Carboplatin
145
Paclitaxel
125
Cyclophosphamide
94
130-nm albumin-bound paclitaxel
66
Capecitabine
64
Gemcitabine
54
Doxorubicin
50
Albumin-Bound Paclitaxel
45
Taxes
42
atezolizumab
41
Cisplatin
38
sacituzumab govitecan
34
Nivolumab
34
olaparib
32
Epirubicin
32
Specimen Handling
28
Docetaxel
28
eribulin
27
Bevacizumab
26
durvalumab
25
Drug Therapy
25
Biopsy
24
camrelizumab
23
Magnetic Resonance Spectroscopy
22
toripalimab
19
Radiotherapy
17
spartalizumab
16
Everolimus
15
veliparib
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
magrolimab
×
Clear all
NCT04958785
2025-11-04
ELEVATE TNBC
Gilead Sciences
Phase 2
Terminated
92 enrolled
27 charts